{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+%2B+PEGinterferon+alfa-2a", "query": { "intervention": "placebo + PEGinterferon alfa-2a" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 56, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+%2B+PEGinterferon+alfa-2a&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-27T08:51:38.740Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00516321", "title": "Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "eltrombopag", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 687, "start_date": "2007-10", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2013-11-05", "last_synced_at": "2026-09-27T08:51:38.740Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 40 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00516321" }, { "nct_id": "NCT01278134", "title": "A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus placebo", "type": "DRUG" }, { "name": "RO5024048", "type": "DRUG" }, { "name": "danoprevir", "type": "DRUG" }, { "name": "peginterferon alfa-2a [Pegasys]", "type": "DRUG" }, { "name": "ribavirin [Copegus]", "type": "DRUG" }, { "name": "ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 170, "start_date": "2011-02", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-27T08:51:38.740Z", "location_count": 18, "location_summary": "La Jolla, California • Sacramento, California • Orlando, Florida + 14 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT01278134" }, { "nct_id": "NCT01170962", "title": "Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "BMS-790052", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "peginterferon alfa-2a", "type": "DRUG" }, { "name": "ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 512, "start_date": "2010-08", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2015-10-12", "last_synced_at": "2026-09-27T08:51:38.740Z", "location_count": 35, "location_summary": "Montgomery, Alabama • La Jolla, California • Los Angeles, California + 28 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01170962" }, { "nct_id": "NCT01323244", "title": "A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "TMC435", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen R&D Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 142, "start_date": "2011-12", "completion_date": "2015-03", "has_results": false, "last_update_posted_date": "2016-04-04", "last_synced_at": "2026-09-27T08:51:38.740Z", "location_count": 15, "location_summary": "Bakersfield, California • Los Angeles, California • San Diego, California + 12 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01323244" }, { "nct_id": "NCT00987337", "title": "Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis", "Hepatitis C" ], "interventions": [ { "name": "Filibuvir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 288, "start_date": "2009-11", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2014-01-27", "last_synced_at": "2026-09-27T08:51:38.740Z", "location_count": 30, "location_summary": "Anaheim, California • Coronado, California • La Jolla, California + 22 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Anaheim", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Mather", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00987337" }, { "nct_id": "NCT01188772", "title": "Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "Sofosbuvir", "type": "DRUG" }, { "name": "Placebo to match sofosbuvir", "type": "DRUG" }, { "name": "PEG", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 147, "start_date": "2010-08", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2014-04-21", "last_synced_at": "2026-09-27T08:51:38.740Z", "location_count": 22, "location_summary": "Montgomery, Alabama • Anaheim, California • Coronado, California + 17 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01188772" }, { "nct_id": "NCT00040027", "title": "Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C", "Hepatitis C, Chronic" ], "interventions": [ { "name": "thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a", "type": "DRUG" }, { "name": "placebo + PEGinterferon alfa-2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SciClone Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2002-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2008-01-15", "last_synced_at": "2026-09-27T08:51:38.740Z", "location_count": 46, "location_summary": "Mobile, Alabama • Scottsdale, Arizona • Berkeley, California + 36 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00040027" }, { "nct_id": "NCT01482403", "title": "A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus", "type": "DRUG" }, { "name": "Pegasys", "type": "DRUG" }, { "name": "boceprevir", "type": "DRUG" }, { "name": "mericitabine", "type": "DRUG" }, { "name": "mericitabine placebo", "type": "DRUG" }, { "name": "boceprevir placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2011-11", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2016-08-05", "last_synced_at": "2026-09-27T08:51:38.740Z", "location_count": 7, "location_summary": "Littleton, Colorado • Chicago, Illinois • Shreveport, Louisiana + 4 more", "locations": [ { "city": "Littleton", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Shreveport", "state": "Louisiana" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01482403" }, { "nct_id": "NCT01257204", "title": "Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Pegylated interferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 196, "start_date": "2010-12", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2015-12-14", "last_synced_at": "2026-09-27T08:51:38.740Z", "location_count": 4, "location_summary": "Los Angeles, California • Baltimore, Maryland • Tulsa, Oklahoma + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Tulsa", "state": "Oklahoma" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01257204" }, { "nct_id": "NCT01318694", "title": "Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Alisporivir", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "ALV Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 1081, "start_date": "2011-03", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2016-09-30", "last_synced_at": "2026-09-27T08:51:38.740Z", "location_count": 32, "location_summary": "Beverly Hills, California • Oakland, California • San Diego, California + 23 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01318694" } ] }